Christopher Shelby, MD
Ophthalmology · Shreveport, LANPI 1861424228
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (46.6%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 28 manufacturers reported payments, led by Alcon Research LLC at 29.7% of the total. Reporting peaked in 2019 at $7,536 and has fallen 69.8% since, to $2,275 in 2025. Among ophthalmology clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 308 payments — averaging $86.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon Research LLC$8K
- Alcon$8K
- Carl Zeiss Meditec, Inc.$5K
- Ivantis, Inc$1K
- Glaukos Corporation$895
- Sight Sciences, Inc.$824
- plus $3K from 22 others
Across 3 payments — averaging $4000.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Rxsight Inc$12K
What the payments were for
- Consulting fees$12,47547%
- Speaking & faculty fees$5,30620%
- Food & beverage$9,00034%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon Research LLC | 3 | $7,950 |
| Alcon | 131 | $7,855 |
| Carl Zeiss Meditec, Inc. | 2 | $5,280 |
| Ivantis, Inc | 10 | $1,093 |
| Glaukos Corporation | 15 | $895 |
| Sight Sciences, Inc. | 37 | $824 |
| Biotissue Holdings Inc. | 15 | $739 |
| AbbVie(2 entities) | 15 | $321 |
| Oyster Point Pharma, Inc. | 11 | $245 |
| Rxsight Inc | 11 | $198 |
| Ellexiscience | 1 | $163 |
| Bausch & Lomb Americas Inc. | 4 | $161 |
| Kala Pharmaceuticals, Inc. | 3 | $158 |
| NEW World Medical,inc. | 8 | $133 |
| Aerie Pharmaceuticals, Inc. | 7 | $108 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 5 | $94 |
| Rayner Intraocular Lenses Limited | 4 | $80 |
| Shire North American Group Inc | 4 | $73 |
| Tarsus Pharmaceuticals, Inc. | 3 | $62 |
| Mallinckrodt Hospital Products Inc. | 3 | $57 |
| Ocular Therapeutix, Inc. | 3 | $56 |
| Novartis | 3 | $55 |
| Johnson & Johnson Surgical Vision, Inc. | 3 | $53 |
| Sun Pharmaceutical Industries Inc. | 2 | $49 |
| Omeros Corporation | 2 | $27 |
| Amgen | 1 | $20 |
| Dompe US, Inc. | 1 | $19 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VisuMax$5,280
- NGENUITY$3,473
- AcrySof IQ PanOptix$1,656
- ORA$1,575
- Hydrus Microstent$934
- LenSx$635
- ARGOS$356
- Clareon$146
- iDoseTR$142
- OMNI(R) SURGICAL SYSTEM (US)$130
- SION SURGICAL INSTRUMENT$130
- iStent inject W$128
- KXL System$128
- Photrexa$128
- Centurion$127
- EYSUVIS$124
- OMNI$121
- iStent inject Trabecular Micro-Bypass System Model G2-M-IS$116
- iAccess Precision Blade$116
How this compares
$26,780 in reported general payments places this provider in the 95th percentile of 286 ophthalmology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 56 | $53,283 |
| TyrvayaVarenicline Tartrate | 21 | $14,516 |
| XiidraLifitegrast | 18 | $14,103 |
| Cyclosporine | 21 | $13,794 |
| LumiganBimatoprost | 17 | $7,074 |
| Latanoprost | 198 | $2,041 |
| Prednisolone Acetate | 42 | $1,746 |
| MoxifloxacinMoxifloxacin Hcl | 24 | $655 |
| Ketorolac Tromethamine | 21 | $558 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 24 | $557 |
| Brimonidine Tartrate | 21 | $509 |
| Timolol Maleate | 25 | $398 |
| Gabapentin | 27 | $54 |
| Temazepam | 38 | $37 |
| Diazepam | 39 | $24 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan | $321 | $60,35773 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $245 | $14,51621 claims |
| Bausch & Lomb Americas Inc.Xiidra | $161 | $14,10318 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 286 ophthalmology providers in Louisiana.
Other ophthalmology in Shreveport
- Wyche ColemanShreveport$35K
- Bryan VekoviusShreveport$29K
- Chanping LiangShreveport$15K
- Claude BundrickShreveport$12K
- Bryan LuskShreveport$10K
- Arthur KavanaughShreveport$7K
- Ann GuyShreveport$6K
- Jeffrey LuskShreveport$5K
- John CarmodyShreveport$5K
- Blake WilliamsonBaton Rouge$443K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.